Every Form 4 that AN2 Therapeutics, Inc. (ANTX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ANTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ANTX filings page.
AN2 Therapeutics, Inc. (ANTX) director Robin Shane Readnour reported indirect sales totaling 1,108 shares of common stock on September 9, 2026, at a weighted average price of $6.0243 per share. The sales were made automatically under Rule 10b5-1 trading plans for MGC 2018 LP and MGC 2018 QP. Following these transactions, Readnour continues to hold 9,077 shares of ANTX common stock directly, while disclaiming beneficial ownership of the fund-held shares beyond any pecuniary interest.
AN2 Therapeutics, Inc. (ANTX) director Robin Shane Readnour reported indirect sales of common stock associated with investment funds MGC Venture Partners 2018, LP and MGC Venture Partners QP 2018, LP on September 3 and 8, 2026. The funds sold a total of 16,119 shares at weighted average prices of $6.0183 and $6.0698 per share, for transactions occurring automatically pursuant to Rule 10b5-1 trading plans adopted on April 23, 2026. Readnour has shared voting and dispositive power over these fund-held shares and disclaims beneficial ownership except to the extent of his pecuniary interest; a separate entry shows 9,077 shares of common stock held directly as of September 3, 2026.
AN2 Therapeutics, Inc. (ANTX) reported that Principal Accounting Officer Sarah Joanne Williams sold 272 shares of common stock on September 1, 2026 at $5.53 per share. The sale was made pursuant to the grant terms to satisfy tax withholding obligations arising from RSU vesting on August 28, 2026.
After this transaction, Williams holds 66,311 shares directly, including RSUs that vest through 2029, subject to her continuous service. No Rule 10b5-1 trading plan is reported for this sale.
AN2 Therapeutics, Inc. (ANTX) director Margaret M. FitzPatrick purchased 2,098 shares of ANTX common stock in a direct open-market or private transaction on September 1, 2026 at $5.53 per share. Following this purchase, she directly holds 10,708 shares of ANTX common stock. No Rule 10b5-1 trading plan is reported.
AN2 Therapeutics, Inc. (ANTX) director Robin Shane Readnour reported indirect sales of common stock on August 17, 2026 through investment partnerships MGC Venture Partners 2018, LP and MGC Venture Partners QP 2018, LP under pre-arranged Rule 10b5-1 trading plans. A total of 35,402 shares of ANTX common stock were sold in open-market or private transactions at a weighted average price of $6.0082 per share, with individual trades ranging from $6.00 to $6.07. Readnour is a managing partner of MGC Venture Partners 2018 GP, LLC, which has shared voting and dispositive power over the partnerships’ holdings, and disclaims beneficial ownership of these securities except to the extent of her pecuniary interest. Separately, she reports 9,077 shares of ANTX common stock held directly.
AN2 Therapeutics director Joseph S. Zakrzewski reported a bona fide gift of 405,880 shares of common stock. The gifted shares were held indirectly through the Z3 Trust, and he disavows beneficial ownership of those shares. Following this transaction, he reports 145,538 shares of AN2 Therapeutics common stock held directly.
Aziz Kabeer reported acquisition or exercise transactions in this Form 4 filing.
AN2 Therapeutics, Inc. director Aziz Kabeer received a grant of 2,852 shares of common stock on July 10, 2026 as compensation under the non-employee director compensation policy, in lieu of cash, with all shares vesting immediately. Following this award, he holds 59,106 shares directly. Additional indirect holdings of 377,542 and 1,995,958 shares are held through Adjuvant Global Health Technology Fund entities, where he may be deemed to share voting and dispositive power but each related person and entity disclaims beneficial ownership except to the extent of pecuniary interest.
Marks Gilbert Lynn reported acquisition or exercise transactions in this Form 4 filing.
AN2 Therapeutics, Inc. director Gilbert Lynn Marks received a grant of 2,789 shares of Common Stock on July 10, 2026. The shares were issued in lieu of cash under the company’s non-employee director compensation policy and vest immediately. Following this award, Marks directly holds 81,873 shares of Common Stock.
Martin Patricia A. reported acquisition or exercise transactions in this Form 4 filing.
AN2 Therapeutics, Inc. director Patricia A. Martin received a grant of 766 shares of Common Stock on July 10, 2026. The shares were issued in lieu of cash fees under the company’s non-employee director compensation policy and vest immediately, bringing her direct holdings to 18,863 shares.
AN2 Therapeutics, Inc. officer Joshua M. Eizen reported an open-market sale of 5,945 shares of common stock at $4.172 per share on July 8, 2026. A footnote explains these shares were sold to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units on July 1, 2026, indicating this was a tax-related disposition rather than a discretionary sale. After the transaction, Eizen held 206,554 shares directly, and this balance reflects the prior purchase of 5,000 shares under the 2022 Employee Stock Purchase Plan on March 31, 2026. The reported holdings also include unvested RSUs scheduled to vest annually over four years from various grant dates in 2024–2026, subject to continued service.
AN2 Therapeutics, Inc. Principal Accounting Officer Sarah Joanne Williams reported a small sale of 265 shares of common stock at $4.43 per share. According to the footnotes, these shares were sold under the grant terms to satisfy tax withholding obligations from Restricted Stock Units that vested on May 29, 2026, making this a routine tax-related transaction rather than a discretionary sale.
After this sale, Williams directly holds 66,583 shares of common stock. She also has unvested RSUs, including 48,375 RSUs vesting over four years from January 1, 2026, 10,938 RSUs vesting over four years from January 1, 2025, and 11,850 RSUs vesting quarterly over four years from May 28, 2024, all subject to continued service. The footnotes note that, from the RSUs under the latter two awards, 3,766 shares have been sold to cover taxes and 814 shares have been sold on the open market.
Aziz Kabeer reported acquisition or exercise transactions in this Form 4 filing.
AN2 Therapeutics director Aziz Kabeer received 3,775 shares of Common Stock as an equity grant. The shares were issued in lieu of cash under the non-employee director compensation policy and vest immediately. Following this award, he holds 56,254 shares directly.
Separate from his direct holdings, 1,995,958 shares are held by Adjuvant Global Health Technology Fund, L.P. and 377,542 shares are held by Adjuvant Global Health Technology Fund DE, L.P. Mr. Kabeer is affiliated with these entities and may be deemed to share voting and dispositive power, but each person and entity disclaims beneficial ownership except for any pecuniary interest.
Marks Gilbert Lynn reported acquisition or exercise transactions in this Form 4 filing.
AN2 Therapeutics director Gilbert Lynn Marks received a stock grant of 3,775 shares of Common Stock on April 10, 2026. The shares were issued in lieu of cash under the company’s non-employee director compensation policy and carry a grant price of $0.00 per share.
All 3,775 shares vest immediately, meaning Marks has full ownership without a vesting schedule. Following this award, he directly holds a total of 79,084 shares of AN2 Therapeutics common stock. This is a compensation-related grant, not an open-market purchase.
AN2 Therapeutics, Inc. director Patricia A. Martin received a grant of common stock as part of non-employee director compensation. She acquired 1,192 shares at a price of $0.00 per share, issued in lieu of cash fees, and now directly holds 18,097 shares. According to the disclosure, all of the awarded shares vest immediately.
AN2 Therapeutics, Inc. Chief Financial Officer Lucy Day reported a repricing and replacement of stock options on March 19, 2026. She received new stock option grants covering 73,665, 66,000 and 82,300 shares of common stock, each with a $3.91 per-share exercise price, matching the issuer’s closing price that day.
On the same date, options over identical share amounts with higher exercise prices of $6.596, $17.28 and $14.29 were disposed of back to the company. One grant is fully vested, while two grants vest monthly in forty‑eight equal installments starting from March 25, 2022 and January 1, 2023, contingent on continued service. The $3.91 exercise price may revert to the original higher price if the options are exercised or service ends before a defined "Premium End Date."
AN2 Therapeutics, Inc. Chief Development Officer Sanjay Chanda reported compensation-related option changes, not open-market trades. On March 19, 2026, three existing stock option awards were repriced so that each now has an exercise price of $3.91 per share, matching the closing common stock price on the repricing date.
Each repriced award covers stock options to buy common stock in amounts of 66,000, 57,950 and 41,665 shares. The filing shows matching dispositions of the prior higher‑priced options back to the issuer. One option is fully vested, while the others vest monthly over 48 months starting March 25, 2022 and January 1, 2023, subject to continuous service.
The new $3.91 exercise price can revert to the original higher exercise price if, before the "Premium End Date", the repriced options are exercised or employment ends. The Premium End Date is the earliest of September 19, 2027, a change in control, or the reporting person's death or disability.
AN2 Therapeutics director Gilbert Lynn Marks reported a repricing of stock options with no open-market trades in common shares. On March 19, 2026, he acquired several new stock option awards covering common stock at an exercise price of $3.91 per share and simultaneously disposed of older options back to the issuer for the same share amounts.
The footnotes state that $3.91 represents the closing price of AN2 Therapeutics’ common stock on the repricing date and that the options are fully vested. The exercise price will revert to the original higher exercise price if the repriced options are exercised or if his service ends before the defined “Premium End Date.”
AN2 Therapeutics director Aziz Kabeer reported a repricing of stock options. On March 19, 2026, he received two grants of stock options for 20,724 and 23,742 shares of common stock, each with a new exercise price of $3.91 per share, matching the closing market price that day.
At the same time, he disposed of the same numbers of older options back to the company that had higher exercise prices of $17.28 and $5.91 per share. The repriced options are fully vested and remain subject to a "Premium End Date" that can cause the exercise price to revert to the original level if certain events occur before September 19, 2027.
AN2 Therapeutics director Patricia A. Martin reported a repricing of several stock options on March 19, 2026. She disposed of three existing options to purchase 24,999, 10,362 and 23,742 shares of common stock at exercise prices of $6.596, $17.28 and $5.91 per share, respectively, and received new, fully vested options for the same share amounts at an exercise price of $3.91 per share.
According to the board-approved terms, the $3.91 exercise price equals the closing stock price on the repricing date and will revert to each option’s original exercise price if the repriced option is exercised or her service ends before the “Premium End Date,” defined as the earliest of September 19, 2027, a change in control, or her death or disability.
AN2 Therapeutics director Margaret M. FitzPatrick reported a board-approved repricing of stock options on the company’s common stock. On March 19, 2026, existing options were surrendered to the issuer and replaced with new fully vested options covering the same number of shares at an exercise price of $3.91 per share.
The repricing keeps all other terms unchanged, except that the exercise price will revert to the original higher level if the repriced options are exercised, or if her service ends, before the “Premium End Date.” The Premium End Date is the earliest of September 19, 2027, a change in control, or her death or disability.
AN2 Therapeutics director Stephanie Wong reported a repricing of multiple stock options on the company’s common stock. On March 19, 2026, she was granted new stock options covering 24,999, 10,362 and 23,742 shares at an exercise price of $3.91 per share, matching the closing market price that day. In corresponding transactions, options over the same numbers of shares with higher exercise prices of $6.596, $17.28 and $5.91 were surrendered to the company.
According to the footnotes, the repriced option is fully vested. The $3.91 exercise price will be increased back to the original exercise price if, before the stated “Premium End Date,” the repriced option is exercised or Wong’s service with the company ends.
AN2 Therapeutics director Joseph S. Zakrzewski reported a board-approved repricing of his stock options. On March 19, 2026, existing options to buy common stock with higher exercise prices were surrendered to the company and replaced with new fully vested options at an exercise price of $3.91 per share.
The new options cover multiple grants of stock options (rights to buy common stock) with expiration dates ranging from April 29, 2031 to June 6, 2033. The filing reflects compensation-related adjustments only and does not show any open-market purchases or sales of AN2 Therapeutics common stock.
AN2 Therapeutics, Inc. reported that officer Joshua M. Eizen had certain stock options repriced on March 19, 2026. He received new options to purchase 92,000 and 50,150 shares of common stock at an exercise price of $3.91 per share, replacing prior options for the same share amounts with higher exercise prices of $17.88 and $14.29.
The footnotes explain that the new exercise price equals the closing market price on the repricing date and that vesting schedules remain as previously set. The filing shows no open-market purchases or sales of common stock, only compensation-related option grants and corresponding cancellations back to the issuer.
AN2 Therapeutics director Melvin K. Spigelman reported a board-approved repricing of his stock options on March 19, 2026. He received three fully vested stock option awards for 16,941, 10,362 and 23,742 underlying common shares at a new exercise price of $3.91 per share, while surrendering an equal number of existing options with higher exercise prices of $9.308, $17.28 and $5.91.
The repriced options keep their original terms except for the exercise price. If any repriced option is exercised, or his service ends, before the “Premium End Date” (the earliest of September 19, 2027, a change in control, or his death or disability), the exercise price reverts to the original higher level. These are compensation-related derivative adjustments, not open-market stock purchases or sales.
AN2 Therapeutics director Robin Shane Readnour reported a repricing of stock options covering 20,724 and 23,742 shares of common stock on March 19, 2026. Existing options with exercise prices of $17.28 and $5.91 per share were returned to the company, and fully vested replacement options were granted at an exercise price of $3.91 per share, equal to the closing stock price on the repricing date.
The footnotes state this new exercise price will revert to the original higher price if the repriced options are exercised, or if Readnour’s service with the company ends, before the defined “Premium End Date,” which is the earliest of September 19, 2027, a change in control, or Readnour’s death or disability.
AN2 Therapeutics Chief Executive Officer Eric Easom reported a repricing of his stock options, with no open-market purchases or sales of common stock. On March 19, 2026, the board approved cancelling existing options with exercise prices of $6.596, $17.28 and $11.99 per share and granting replacement options over the same share amounts at an exercise price of $3.91 per share, matching the closing stock price that day.
The replacement options remain subject to their original expiration dates and vesting schedules, including monthly vesting measured from March 25, 2022 and January 1, 2023, as applicable. The footnotes state that if the repriced options are exercised, or Easom’s service ends, before a defined “Premium End Date,” the exercise price will revert to the original higher levels.
AN2 Therapeutics principal accounting officer Sarah Joanne Williams sold 327 shares of common stock at $1.06 per share. The March 3, 2026 open‑market sale was made under grant terms to satisfy tax withholding from Restricted Stock Units vesting on February 28, 2026. After this transaction she directly holds 66,848 shares, and her holdings include multiple RSU awards that vest in installments through future years, subject to her continued service.
Eizen Joshua M reported acquisition or exercise transactions in this Form 4 filing.
AN2 Therapeutics officer Joshua M. Eizen reported new equity awards. He was granted a stock option covering 100,000 shares, which vests in equal monthly installments over four years from January 1, 2026, subject to continued service. He also received 50,000 restricted stock units that vest 25% annually over four years from January 1, 2026, on the same service condition. Following these awards, he directly owns 207,499 shares of common stock, which includes prior RSU grants and a 5,000-share purchase under the 2022 Employee Stock Purchase Plan on March 31, 2025.
Day Lucy reported acquisition or exercise transactions in this Form 4 filing.
AN2 Therapeutics, Inc. Chief Financial Officer Lucy Day reported equity awards consisting of a stock option for 77,000 shares and a grant of 38,000 shares of common stock on February 20, 2026. The common stock amount represents restricted stock units that vest 1/4 annually over four years from January 1, 2026, subject to continued service. The option vests 1/48 monthly over four years from the same date on a continued-service basis. Her common stock holdings total 118,363 shares, reflecting prior RSU grants of 27,500 and 46,500 units with annual vesting from January 1, 2024 and January 1, 2025, and a 5,000-share purchase under the 2022 Employee Stock Purchase Plan on March 31, 2025.
Williams Sarah Joanne reported acquisition or exercise transactions in this Form 4 filing.
AN2 Therapeutics Principal Accounting Officer Sarah Joanne Williams received a grant of 48,375 shares of common stock in the form of restricted stock units. The RSUs vest over four years, with one quarter of the shares vesting annually from January 1, 2026, contingent on her continued service.
After this award, Williams directly holds 67,175 shares, including prior RSU grants described in the footnotes. Those earlier RSUs vest on separate annual and quarterly schedules, also conditioned on her remaining in service with the company.
AN2 Therapeutics, Inc. director and Chief Executive Officer Eric Easom reported new equity awards. He received a stock option for 224,500 shares at an exercise price of $0.0000 per share and a grant of 112,250 shares of Common Stock on February 20, 2026.
The 112,250-share grant represents restricted stock units that vest in 25% increments annually over four years from January 1, 2026, subject to continuous service. The option vests 1/48 of the shares monthly over four years from January 1, 2026. Easom also reports indirect ownership of Common Stock through the Easom Living Trust and two irrevocable trusts.
AN2 Therapeutics Chief Development Officer Sanjay Chanda reported new equity awards. On February 20, 2026, he received a grant of stock options for 77,000 shares at an exercise price of $0.00 per share, vesting monthly over four years from January 1, 2026.
He also acquired 38,000 shares of common stock as restricted stock units that vest annually in four installments from January 1, 2026, subject to continued service. Following these awards, he directly holds 77,000 options and 118,823 common shares, which include previously granted RSUs and shares purchased under the 2022 Employee Stock Purchase Plan.
Marks Gilbert Lynn reported acquisition or exercise transactions in this Form 4 filing.
AN2 Therapeutics director Marks Gilbert Lynn reported receiving a grant of stock options covering 20,400 shares. The options are scheduled to vest on February 20, 2027, provided he continues to provide service to the company through that date.
Readnour Robin Shane reported acquisition or exercise transactions in this Form 4 filing.
AN2 Therapeutics director Robin Shane Readnour reported an equity award in the form of stock options for 20,400 shares. The options were granted as a compensation award and will vest on February 20, 2027, provided Readnour continues to provide service to the company through that date.
AN2 Therapeutics, Inc. director Stephanie Wong received a grant of stock options covering 20,400 shares on February 20, 2026. The options were granted at an exercise price of $0.00 per share and will vest on February 20, 2027, provided she continues to serve through that date.
AN2 Therapeutics director Patricia A. Martin received a stock option grant for 20,400 shares of common stock of AN2 Therapeutics, Inc. The option was awarded at an exercise price of $0.00 per share, reflecting a compensatory grant rather than an open-market purchase.
The option shares will vest on February 20, 2027, provided Martin continues to provide service to the company through that date. Following this award, she holds 20,400 option shares directly, aligning her compensation more closely with the company’s future share performance.
AN2 Therapeutics, Inc. director Melvin K. Spigelman reported receiving a grant of stock options covering 20,400 shares of the company’s stock. The award was recorded as an acquisition of derivative securities held directly by him. According to the filing, these option shares will vest on February 20, 2027, provided he continues to provide service to the company through that date.
AN2 Therapeutics director Aziz Kabeer received a grant of 20,400 stock options (right to buy) on February 20, 2026. The options have an exercise price of $0.00 per share and are held directly.
The option shares are scheduled to vest on February 20, 2027, provided Kabeer continues to provide service to the company through that date. After this grant, he holds 20,400 derivative securities related to the company’s stock options.
AN2 Therapeutics director Margaret M. FitzPatrick received a grant of stock options for 20,400 shares of AN2 Therapeutics, Inc. common stock. The options carry an exercise price of $0.00 per share and are reported as a direct derivative holding.
The option shares are scheduled to vest on February 20, 2027, provided FitzPatrick continues to provide service to the company through that date. After this award, she holds a total of 20,400 stock options according to the filing.
Zakrzewski Joseph S reported acquisition or exercise transactions in this Form 4 filing.
AN2 Therapeutics director Joseph S. Zakrzewski reported receiving a grant of stock options for 20,400 shares on February 20, 2026. These options were awarded at no purchase price on the grant date and represent his total reported derivative holdings of 20,400 options after the transaction.
According to the disclosure, the option shares will vest on February 20, 2027, provided he continues to provide service to the company through that date. This filing reflects an equity-based compensation award rather than an open‑market purchase or sale.
AN2 Therapeutics director Kabeer Aziz received 11,560 shares of common stock on January 12, 2026 as equity compensation. The shares were issued in lieu of cash under the company’s non-employee director compensation policy and all of them vest immediately. Following this grant, Aziz directly holds 52,479 shares of AN2 Therapeutics common stock.
In addition, entities associated with Aziz hold significant indirect positions. Adjuvant Global Health Technology Fund, L.P. holds 1,995,958 shares and Adjuvant Global Health Technology Fund DE, L.P. holds 377,542 shares, with their general partners and management entities involved in voting and dispositive power. Each person and entity, including Aziz, disclaims beneficial ownership of these indirectly held shares except to the extent of any pecuniary interest.
AN2 Therapeutics director Patricia A. Martin received 3,650 shares of common stock on 01/12/2026 as equity compensation. The shares were issued in lieu of cash under the company’s non-employee director compensation policy and all of them vest immediately, meaning there is no waiting period before they belong to her. Following this grant, Martin beneficially owns 16,905 shares of AN2 Therapeutics common stock, held directly.
AN2 Therapeutics director Gilbert Lynn Marks reported a stock-based compensation grant of 11,560 shares of common stock on January 12, 2026. The shares were issued at a price of $0.00 per share under the company’s non-employee director compensation policy, in lieu of cash fees. According to the disclosure, all of these shares vest immediately.
Following this transaction, Marks directly beneficially owns 75,309 shares of AN2 Therapeutics common stock. The filing characterizes this as a routine equity grant for board service rather than an open-market purchase or sale.
AN2 Therapeutics, Inc. Chief Financial Officer Lucy Day reported two sales of company common stock. On January 5, 2026, she sold 3,295 shares at $1.003 per share, and on January 6, 2026, she sold 5,512 shares at $1.012 per share. According to the disclosure, these sales were made under the terms of the equity grant to satisfy tax withholding obligations arising from the vesting of restricted stock units on January 1, 2026.
After these transactions, Day directly holds 75,363 shares of AN2 Therapeutics common stock. Her equity awards also include 27,500 RSUs that vest in four annual installments starting January 1, 2024, and 46,500 RSUs that vest in four annual installments starting January 1, 2025, in each case subject to her continued service. The reported total reflects a prior purchase of 5,000 shares through the company’s employee stock purchase plan on September 30, 2025.
AN2 Therapeutics Chief Strategy Officer Stephen David Prior reported two small stock sales related to tax withholding on recently vested equity awards. On January 5, 2026, he sold 3,604 shares of common stock at $1.003 per share, and on January 6, 2026 he sold 2,858 shares at $1.012 per share. The filing explains that these sales were made under the terms of the grant to satisfy tax withholding obligations arising from the vesting of restricted stock units on January 1, 2026. After the January 6 transaction, he beneficially owned 59,086 shares of common stock directly.
The filing also notes ongoing equity incentives: 10,125 RSUs vest over four years from November 4, 2024, 17,500 RSUs follow a schedule through January 1, 2026, and 28,000 RSUs vest over four years from January 1, 2025, in each case subject to continued service.
AN2 Therapeutics Chief Development Officer Sanjay Chanda reported two sales of AN2 Therapeutics common stock. On January 5, 2026, he sold 3,295 shares at $1.003 per share, and on January 6, 2026, he sold 5,956 shares at $1.012 per share. A footnote states these shares were sold under the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units (RSUs) on January 1, 2026, rather than as discretionary open‑market sales.
After these transactions, Chanda beneficially owned 75,823 shares of common stock directly. This amount includes 27,500 RSUs that vest annually in four equal parts from January 1, 2024, and 50,250 RSUs that vest annually in four equal parts from January 1, 2025, in each case subject to his continued service. The total also reflects a prior purchase of 5,000 shares under the company’s Employee Stock Purchase Plan on September 30, 2025.
AN2 Therapeutics officer reports small stock sales tied to RSU taxes. Chief Operating Officer and Chief Legal Officer Joshua M. Eizen reported selling 17,923 shares of AN2 Therapeutics common stock on January 5, 2026 at a weighted average price of $1.0014 per share, followed by 6,931 shares on January 6, 2026 at $1.012 per share. According to the footnotes, these shares were sold pursuant to the terms of the equity grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units on January 1, 2026. After the reported transactions, Eizen directly beneficially owned 152,499 shares of common stock, which include multiple RSU awards that vest over several years, subject to his continued service.
AN2 Therapeutics (ANTX) insider activity: Chief Operating Officer and Chief Legal Officer Joshua M. Eizen reported selling 2,819 shares of common stock at $1.14 on November 4, 2025, to satisfy tax withholding from RSU vesting. Following the transaction, he beneficially owns 177,353 shares.
The holdings figure includes RSU grants: 31,500 RSUs vesting annually in quarters from November 4, 2024; 22,500 RSUs vesting annually in thirds from January 1, 2025; and 45,000 RSUs with two-thirds vesting on January 1, 2026 and one-third on July 1, 2026, subject to continuous service. The total also reflects the purchase of 5,000 shares under the 2022 ESPP on September 30, 2025.
AN2 Therapeutics (ANTX) reported an insider transaction by Chief Strategy Officer Stephen David Prior. On 11/04/2025, he sold 765 shares of common stock at $1.14 per share, a sale made to satisfy tax withholding from the vesting of RSUs. Following this transaction, he beneficially owned 65,548 shares.
His equity includes 10,125 RSUs that vest 1/4 annually over four years from November 4, 2024, and 12,031 RSUs that vest on January 1, 2026, each contingent on continued service. The holdings also reflect the purchase of 5,000 shares under the 2022 Employee Stock Purchase Plan on September 30, 2025.
AN2 Therapeutics (ANTX) reported a director’s acquisition of 10,367 shares of common stock on 10/10/2025 via Form 4. The shares were issued in lieu of cash compensation under the company’s non‑employee director policy, and all shares vest immediately. The transaction was coded A and reported at a price of $0. Following this transaction, the director beneficially owned 63,749 shares, held directly.